← FDA DRUG APPROVALS

FDA ANDA · ANDA207624

SEVELAMER CARBONATE

Sponsor: AUROBINDO PHARMA

APPLICATION
ANDA207624
TYPE
ANDA
ORIGINAL APPROVAL
2017-06-13
LATEST ACTION
2022-04-05
ROUTE
ORAL
DOSAGE FORM
FOR SUSPENSION
MARKETING STATUS
Prescription

Products

SEVELAMER CARBONATEPrescription
SEVELAMER CARBONATE 800MG/PACKET · FOR SUSPENSION · ORAL
SEVELAMER CARBONATEPrescription
SEVELAMER CARBONATE 2.4GM/PACKET · FOR SUSPENSION · ORAL

Approval history

2022-04-05Labeling · Supplement 3 · standardAP
2020-03-25Labeling · Supplement 1 · standardAP
2017-06-13UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →